All In Biotech

Drug Trial Radar · NCT07911579

A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors

A Phase Ib/ II Clinical Study to Evaluate the Safety and Efficacy of SYH2051 in Combination With Irinotecan Hydrochloride Liposome in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, dose-escalation and dose expansion, and cohort-expansion phase Ib/II clinical study to evaluate the safety and antitumor efficacy of SYH2051 in combination with Irinotecan Hydrochloride Liposome Injection in Patients with Advanced Solid Tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SYH2051Drug

    SYH2051 is an oral medication taken once daily, with dosage selected according to the dose group.

  • Irinotecan Hydrochloride Liposome.Drug

    Irinotecan Hydrochloride Liposome is administered by intravenous infusion every 2 weeks (Q2W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: From Day 1 to Day 28
  2. Frequency and severity of AETime frame: From Day 1 to 12 months.
  3. Maximal tolerable dose (MTD)Time frame: From Day 1 to 12 months.
  4. Recommended phase 2 dose (RP2D)Time frame: From Day 1 to 12 months.
  5. ORRTime frame: From Day 1 to 12 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.